The Intestinal Microbiota and Liver Disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The gut and the liver are intimately associated, and there is continuous bidirectional communication between these organs through the bile, hormones, inflammatory mediators, and products of digestion and absorption. Thus, the quantity, quality, and composition of the intestinal microbiota should be expected to have both direct and indirect effects on liver disease and liver function. Although there is a paucity of data, the microbiota may be related to the development and progression of nonalcoholic fatty liver disease (NAFLD). The microbiota are thought to influence the development and progression of NAFLD through modulating fat deposition and insulin sensitivity as well as influencing luminal bacterial choline metabolism, increasing gut luminal acetaldehyde and ethanol production, and/or through production of lipopolysaccharide and induction of the inflammatory cascade. In patients with cirrhosis, the microbiota are implicated in the development of hepatic encephalopathy (HE) and other complications, including spontaneous bacterial peritonitis and esophageal variceal bleeding. The efficacy of modulating the gastrointestinal flora in HE has been extensively studied; positive effects have been observed for prebiotics, probiotics, and synbiotics. Recently, the nonabsorbable antibiotic, rifaximin, has demonstrated considerable efficacy in the long-term prevention of HE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
Rifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164
Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042
Characterization of fecal microbial communities in patients with liver cirrhosis
Chen, Y., Yang, F., Lu, H., Wang, B., Chen, Y., Lei, D., Wang, Y., Zhu, B., & Li, L. (2011) · Hepatology · doi:10.1002/hep.24423 · Cited by 1,038
Linkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547
Self-citationThe role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Formation of methylamines from ingested choline and lecithin.
Zeisel, S. H., Wishnok, J. S., & Blusztajn, J. K. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33590-1 · Cited by 253
Review article: the modern management of hepatic encephalopathy
BAJAJ, J. S. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04211.x · Cited by 243
Self-citation
Cited by
Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
“Several studies have demonstrated that the gut microbiota affects NAFLD pathogenesis.((12-17)) The widespread epidemic of obesity and diabetes and the diversity in presentation at the individual level might be explained by the relationship between the host and the intestinal microbiota.”
BackgroundYounossi, Z., & Henry, L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.005 · Cited by 334
Self-citationGenome-wide association study of multisite chronic pain in UK Biobank
Johnston, K. J. A., Adams, M. J., Nicholl, B. I., Ward, J., Strawbridge, R. J., Ferguson, A., McIntosh, A. M., Bailey, M. E. S., & Smith, D. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008164 · Cited by 266
Targeting gut microbiome: a novel and potential therapy for autism
Yang, Y., Tian, J., & Yang, B. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.027 · Cited by 140
Gut microbiome approaches to treat obesity in humans
Bianchi, F., Duque, A. L. R. F., Saad, S. M. I., & Sivieri, K. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9570-8 · Cited by 63
Metadata
- Authors
- Bajaj, J. S., Hylemon, P. B., & Younossi, Z.
- Venue
- The American Journal of Gastroenterology Supplements
- Published
- 2012-07
- Volume
- 1
- Issue
- 1
- Pages
- 9-14
- ISSN
- 1948-9498 (ISSN-L)
- 1948-9501
- OpenAlex
- W2023619426
- Cited by
- 56
- References
- 10
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Intestinal Microbiota and Liver Disease. https://app.cochat.ai/papers/10.1038/ajgsup.2012.3
- The paper
- Bajaj, J. S., Hylemon, P. B., & Younossi, Z. (2012). The Intestinal Microbiota and Liver Disease. The American Journal of Gastroenterology Supplements. https://doi.org/10.1038/ajgsup.2012.3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.